Device Trial Radar · NCT03417817
Oesophageal Acid Exposure in Healthy Subjects Over 96 Hours
Last checked: Nov 19, 2026Latest source record: Aug 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 16, 2018
Primary completion
Jun 30, 2019
Study completion Jun 30, 2019
Sponsor
- Lead sponsor
- Guy's and St Thomas' NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 31, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
First introduced over 40 years ago, the 24-hour catheter-based pH studies have previously been found to be the gold standard in the diagnosis of gastro-oesophageal reflux disease (GORD). In 2003, the Bravo has revolutionised the study of GORD, allowing patients an improved comfort and ability to perform activities of daily living. The backflow of gastric acid (acid exposure) in the oesophagus is monitored by a tiny pH sensor located in a capsule which is pinned temporarily to the wall of the oesophagus at the time of endoscopy. Normal measurements for acid exposure are established for 48-hour studies. However, the investigators' studies have shown that extending the duration of recording to 96 hours further improved the diagnostic yield for GORD in patients with negative 24-hour catheter-based tests The 96-hour recording is the current standard of care, despite the lack of normal ranges for this duration of the recording. The basis for the diagnosis of GORD in 96-hours studies is based on the 48-hours normal controls. The objective of this study is to determine the normal values for oesophageal acid exposure using the wireless pH recording apparatus over 96 hours in asymptomatic healthy subjects with unrestricted activity and diet.
Conditions
- Gastroesophageal Reflux
Interventions
BravoDevice
wireless pH monitoring over 96 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acid exposure time in 4 days/96 hoursTime frame: 4 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
King's College London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.